StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

Ultragenyx Pharmaceutical gross margin

Gross margin is gross profit as a percentage of revenue.

Ultragenyx Pharmaceutical's gross margin for the twelve months ending Jun 30, 2019 was 97.2%. For fiscal 2018 it was 97.8%, against 100.0% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2018Dec 31, 201897.8%−2.2
FY2017Dec 31, 2017100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2019Jun 30, 201996.8%−2.1
Q1 FY2019Mar 31, 201997.5%−0.4
Q4 FY2018Dec 31, 201896.9%–
Q3 FY2018Sep 30, 201897.7%–
Q2 FY2018Jun 30, 201898.9%–
Q1 FY2018Mar 31, 201897.9%–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?